TherapeuticsMD (TXMD) Stock: Buy, Sell, or Hold?
TXMD - TherapeuticsMD, Inc.
$1.85
-0.05 (-2.63%)
▼
5d:
-4.14%
30d:
-14.74%
90d:
-10.19%
BUY
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 11, 2026
19d
Get Alerted When TXMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TXMD shows positive signals but monitor for confirmation. Moderate conviction.
💡 BUY OPPORTUNITY: TXMD shows positive signals but monitor for confirmation. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TXMD is currently trading at $1.85, which is considered oversold relative to its 30-day fair value range of $1.94 to $2.14.
Technical Outlook: Technically, TXMD is showing sideways momentum. Immediate support is located at $1.75, while resistance sits at $2.06.
Market Sentiment: TXMD scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.00 (+163.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TXMD is showing sideways momentum. Immediate support is located at $1.75, while resistance sits at $2.06.
Market Sentiment: TXMD scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.00 (+163.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.94 -
$2.14
Company Quality Score
59/100
(HOLD)
Options IV Signal
3th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
95.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 3th percentile)
- BULLISH: Strong technical setup (61/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 163.2% below Wall St target ($5.00)
- BULLISH: Bottoming setup score 61/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.94 -
$2.14
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.34
(18.6%)
Support & Resistance Levels
Support Level
$1.75
Resistance Level
$2.06
Current Trend
Sideways
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.33
Wall Street Target
$5.00
(+163.2%)
Revenue Growth (YoY)
-8.7%
Earnings Growth (YoY)
-80.6%
Profit Margin
-6.6%
Share & Embed Analysis
Last updated: October 22, 2026 1:15 PM ET
Data refreshes hourly during market hours. Next update: 2:15 PM
Data refreshes hourly during market hours. Next update: 2:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TXMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
